Published in Bull World Health Organ on June 01, 2004
Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health (2009) 4.69
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (2013) 3.36
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
HIV prevalence, previous HIV testing, and condom use with clients and regular partners among Senegalese commercial sex workers. Sex Transm Infect (2007) 1.91
Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med (2013) 1.73
Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Public Health (2010) 1.58
Disease progression among untreated HIV-infected patients in South Ethiopia: implications for patient care. MedGenMed (2005) 1.30
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One (2012) 1.13
Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors. J Med Chem (2009) 1.12
Aflatoxin-related immune dysfunction in health and in human immunodeficiency virus disease. Clin Dev Immunol (2008) 1.07
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother (2007) 1.05
Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology (2010) 1.00
Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. AIDS Res Treat (2011) 0.96
HIV morbidity and mortality in Jamaica: analysis of national surveillance data, 1993--2005. Int J Infect Dis (2007) 0.94
The Age Pattern of Increases in Mortality Affected by HIV: Bayesian Fit of the Heligman-Pollard Model to Data from the Agincourt HDSS Field Site in Rural Northeast South Africa. Demogr Res (2013) 0.89
Disease Progression Among Untreated HIV-Infected Patients in South Ethiopia: Implications for Patient Care. J Int AIDS Soc (2005) 0.88
Chronology and evolution of the HIV-1 subtype C epidemic in Ethiopia. AIDS (2010) 0.87
Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. J Clin Microbiol (2006) 0.83
Estimating the capacity for ART provision in Tanzania with the use of data on staff productivity and patient losses. PLoS One (2009) 0.82
Development of a clinical scoring system for assessment of immunosuppression in patients with tuberculosis and HIV infection without access to CD4 cell testing--results from a cross-sectional study in Ethiopia. Glob Health Action (2014) 0.81
Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS One (2012) 0.81
Disease dynamics and costly punishment can foster socially imposed monogamy. Nat Commun (2016) 0.78
High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences. Retrovirology (2013) 0.78
HIV-2 infection in Providence, Rhode Island from 2002 to 2011. HIV Med (2012) 0.76
Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection. J Virus Erad (2017) 0.75
Human immunodeficiency virus type 2 in two Saudi families. Ann Saudi Med (2011) 0.75
HIV infection. BMJ Clin Evid (2008) 0.75
Mortality and survival patterns of people living with HIV-2. Curr Opin HIV AIDS (2016) 0.75
Human Immunodeficiency Virus (HIV). Transfus Med Hemother (2016) 0.75
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med (2016) 6.22
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS (2008) 5.26
Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis (2011) 5.02
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis (2013) 4.26
A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med (2014) 4.07
Evaluation of a home-based voluntary counselling and testing intervention in rural Uganda. Health Policy Plan (2005) 3.30
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS (2007) 3.19
HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural population cohort 1989-2005. AIDS (2008) 3.01
Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis (2002) 2.60
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS (2010) 2.60
Obstacles to conducting epidemiological research in the UK general population. BMJ (2004) 2.59
Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol (2004) 2.58
Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis (2002) 2.54
Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. BMJ (2010) 2.52
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood (2010) 2.49
Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J (2012) 2.46
Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis (2008) 2.42
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis (2006) 2.29
Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis (2008) 2.26
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS (2007) 2.24
Validation of the diagnosis of autism in general practitioner records. BMC Public Health (2004) 2.22
Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomised controlled trial. BMJ (2010) 2.18
Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol Health Med (2007) 2.08
HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med (2009) 2.07
HIV and mortality of mothers and children: evidence from cohort studies in Uganda, Tanzania, and Malawi. Epidemiology (2005) 2.04
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2006) 2.04
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2010) 2.04
MMR vaccination and pervasive developmental disorders: a case-control study. Lancet (2004) 2.02
Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol (2002) 1.98
An epidemiological study of RSV infection in the Gambia. Bull World Health Organ (2002) 1.97
"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health (2008) 1.96
Effect of 50,000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial. BMJ (2008) 1.91
CT-derived estimation of cochlear morphology and electrode array position in relation to word recognition in Nucleus-22 recipients. J Assoc Res Otolaryngol (2002) 1.91
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood (2010) 1.89
NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res (2010) 1.87
Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest (2003) 1.85
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. Genes Cancer (2010) 1.80
Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review. Trop Med Int Health (2012) 1.78
Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol (2006) 1.76
Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine (2007) 1.74
Eosinophilia in returning travellers and migrants from the tropics: UK recommendations for investigation and initial management. J Infect (2010) 1.73
First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine (2008) 1.71
The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology (2004) 1.69
Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med (2011) 1.68
Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review. Trop Med Int Health (2012) 1.66
Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res (2009) 1.65
HIV-1 disease progression and fertility: the incidence of recognized pregnancy and pregnancy outcome in Uganda. AIDS (2004) 1.63
A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings. Open AIDS J (2007) 1.60
Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine (2009) 1.59
HIV/AIDS treatment and HIV vaccines for Africa. Lancet (2002) 1.58
The incubation period of kuru. Epidemiology (2002) 1.56
MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives. Vaccine (2008) 1.55
Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med (2012) 1.55
Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS One (2012) 1.53
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS (2003) 1.51
Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res (2011) 1.51
Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS (2010) 1.50
249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene (2005) 1.49
Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis (2007) 1.49
Early risk assessment for viral haemorrhagic fever: experience at the Hospital for Tropical Diseases, London, UK. J Infect (2006) 1.47
20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.44
Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol (2006) 1.44
Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause (2012) 1.43
Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol (2010) 1.42
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis (2008) 1.41
Malaria in camps for internally-displaced persons in Uganda: evaluation of an insecticide-treated bednet distribution programme. Trans R Soc Trop Med Hyg (2004) 1.40
Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr (2012) 1.39
Antiretroviral treatment in resource-poor settings: public health research priorities. Trop Med Int Health (2005) 1.37
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS (2008) 1.32
Patient attrition between diagnosis with HIV in pregnancy-related services and long-term HIV care and treatment services in Kenya: a retrospective study. J Acquir Immune Defic Syndr (2012) 1.31
Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res (2011) 1.31
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health (2010) 1.30
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One (2013) 1.29
Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J (2010) 1.29
The effect of high-dose vitamin A supplementation administered with BCG vaccine at birth may be modified by subsequent DTP vaccination. Vaccine (2009) 1.28
Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality and no difference in male mortality in a cohort of low birthweight children: an observational study within a randomised trial. Arch Dis Child (2012) 1.28
Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine (2011) 1.27
Evaluation of the dried blood spot filter paper technology and five testing strategies of HIV-1 and HIV-2 infections in West Africa. Scand J Infect Dis (2006) 1.26
Cytomegalovirus infection in Gambian infants leads to profound CD8 T-cell differentiation. J Virol (2007) 1.26
A guide for diagnostic evaluations. Nat Rev Microbiol (2006) 1.25
Reaching millennium development goal 4 - the Gambia. Trop Med Int Health (2011) 1.25
Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One (2011) 1.22
Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect (2008) 1.22
Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr (2011) 1.22
Women who fall by the roadside: gender, sexual risk and alcohol in rural Uganda. Addiction (2006) 1.21
The European and developing countries clinical trails partnership. J HIV Ther (2004) 1.20
Interactions between HIV and malaria in non-pregnant adults: evidence and implications. AIDS (2006) 1.20
Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell (2012) 1.19
Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. J Acquir Immune Defic Syndr (2013) 1.18
Does tuberculosis increase HIV load? J Infect Dis (2004) 1.18